Cybin Inc. CLXPF Archives

WednesdayAug 04, 2021 10:35 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Begin Trading on NYSE American

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that on trading opens on Aug. 5, 2021, its common shares will be trading on the NYSE American LLC stock exchange; the shares will trade under the symbol CYBN. According to the announcement, Cybin’s common shares will also continue to trade in Canada on the NEO Exchange in Canadian dollars; those shares will also trade under the symbol CYBN. The company advised shareholders who purchased over-the-counter (“OTC”) share, including those whose shares are denoted with the CLXPF symbol, to check their account to make sure…

ThursdayJul 29, 2021 9:46 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has received approval for its common shares to trade on the NYSE American LLC stock exchange. According to the announcement, the company anticipates that trading to begin on or about Aug. 5, 2021; the company will trade on the exchange using the symbol CYBN. The company will continue to list its common shares in Canada on the NEO Exchange under the symbol CYBN and on the Frankfurt Stock Exchange under the symbol R7E1. Shareholders are encouraged to check their accounts to make sure that change in exchange…

WednesdayJul 28, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy

Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable the evaluation of patient outcomes Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy. “The digital therapeutics platform, which is proprietary to Cybin and the…

ThursdayJul 22, 2021 9:36 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be moving exchanges. The company has announced that it received conditional listing approval from the NYSE American LLC stock exchange. The NYSE American is designed for growing companies and offers investors a variety of ways in which to trade. The exchange is a competitively priced venue that blends unique features derived from the NYSE, such as electronic Designated Market Makers (“e-DMMs”) with quoting obligations for each NYSE American-listed company, with NYSE Arca’s fully electronic price/time priority execution model. The company noted in making the announcement that…

WednesdayJul 21, 2021 1:26 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Moving Psychedelic Therapeutics Field Forward Through Partnership

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress. The recently launched EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine. Cybin has co-sponsored the study — which will be led by Dr. Anthony Back, a recognized leader in the fields of palliative care and oncology — in a strategic collaboration with the University of Washington. The study will examine treating…

TuesdayJul 20, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz). A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory…

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

TuesdayJul 13, 2021 9:46 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent as Part of Digital Therapeutics Strategy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition, the company is also advancing the build-out of its digital therapeutics strategy, with the objective of evolving its programs beyond the psychedelic molecule into an eco-system with potential to improve patient treatments. A newly formed patient steering company is part of the company’s focus on its digital therapeutics platform, designed to better support the evaluation of patient outcomes through a highly secure, patient-centered data analytics…

FridayJul 09, 2021 9:32 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Notes European Expansion, IP Portfolio Updates, to Participate in Neuropsychiatry Virtual Summit

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is increasing its focus and research activities in Europe. The company announced that it is working with several academic and clinical research organizations as part of those efforts, which include the transfer of its intellectual property assets to its recently formed wholly owned Ireland subsidiary. According to the announcement, Cybin will also continue building its IP portfolio of novel psychedelic compounds, delivery platforms and methods of use in psychiatric indications. The company noted that its growing portfolio of intellectual property includes 12 patent filings and four active…

TuesdayJul 06, 2021 10:25 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Agreement with US Mental Health Chain Group

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has entered into an exclusive research and development collaboration agreement with TMS NeuroHealth Centers Inc. (“TMS”). TMS is a wholly owned subsidiary of Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH), a group of 129 outpatient mental health service centers located across the United States. According to the announcement, Cybin and Greenbrook will partner together to establish that the two companies call Mental Health Centers of Excellence; the centers will focus on facilitating R&D of pioneering psychedelic compound-based therapeutics for individuals struggling with depression. Cybin and Greenbrook bring…

Site Search

Company Search

Tag: Cybin Inc. CLXPF

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Begin Trading on NYSE American

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Moving Psychedelic Therapeutics Field Forward Through Partnership

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent as Part of Digital Therapeutics Strategy

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Notes European Expansion, IP Portfolio Updates, to Participate in Neuropsychiatry Virtual Summit

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Agreement with US Mental Health Chain Group

Market Basics

Newsletter Publishers

Public Companies